v3.25.4
Mergers, Acquisition of Opus Genetics, Fair Value (Details) - Opus Genetics, Inc. [Member]
$ in Thousands
Oct. 22, 2024
USD ($)
Fair Value of Net Assets Acquired [Abstract]  
Cash acquired $ 1,210
Net liabilities assumed (955)
IPR&D 28,000 [1]
Net assets and IPR&D acquired $ 28,255
Discount Rate 20.00%
[1] Represents the Private Opus Acquisition research and development projects which were in-process, but not yet completed, and which the Company may advance post the Opus Acquisition. This includes the development of gene therapies for IRDs. Current accounting standards require that the fair value of IPR&D projects acquired in an asset acquisition with no alternative future use be charged to expense on the acquisition date. The acquired IPR&D did not have outputs or employees. The fair value of the IPR&D was recorded at fair value using Level 3 inputs. A Multi-Period Excess Earnings Method (“MPEEM”) model was applied which incorporates assumptions such as future earnings and margins in connection with the further development and commercialization of IRD therapies, and a discount rate of 20%.